Literature DB >> 1471539

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging.

T Fujimoto1, T Nakano, T Takano, Y Hokazono, T Asakura, T Tsuji.   

Abstract

Phosphorus-31 chemical shift imaging showed regional abnormalities of in vivo 31P NMR spectra in the brains of chronic schizophrenic patients. In the left temporal region, the level of % phosphodiesters (PDE) was increased and the level of % gamma alpha beta-ATP (obtained by summation of gamma-ATP, alpha-ATP, and beta-ATP) was decreased. In the basal ganglia, the levels of % PDE were decreased and the level of % phosphomonoesters was increased. The levels of % gamma alpha beta-ATP were increased in the right basal ganglia. The level of % phosphocreatine was decreased in the frontoparietal region. These findings may represent different patterns of dysfunction of membrane phospholipid bilayers and high-energy phosphate metabolism in the specific cerebral regions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471539     DOI: 10.1111/j.1600-0447.1992.tb03297.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

Review 1.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

2.  Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies.

Authors:  Connor S Haszto; Jeffrey A Stanley; Satish Iyengar; Konasale M Prasad
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-10-01

Review 3.  Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia.

Authors:  Hayley B Clay; Stephanie Sillivan; Christine Konradi
Journal:  Int J Dev Neurosci       Date:  2010-09-15       Impact factor: 2.457

Review 4.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

Review 5.  Impaired mitochondrial function in psychiatric disorders.

Authors:  Husseini Manji; Tadafumi Kato; Nicholas A Di Prospero; Seth Ness; M Flint Beal; Michael Krams; Guang Chen
Journal:  Nat Rev Neurosci       Date:  2012-04-18       Impact factor: 34.870

6.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

7.  31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms.

Authors:  H Fukuzako; K Takeuchi; K Ueyama; T Fukuzako; Y Hokazono; K Hirakawa; K Yamada; T Hashiguchi; M Takigawa; T Fujimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.

Authors:  Asli Ercan Dogan; Cagri Yuksel; Fei Du; Virginie-Anne Chouinard; Dost Öngür
Journal:  Neuropsychopharmacology       Date:  2018-03-14       Impact factor: 7.853

Review 9.  Mitochondrial dysfunction and psychiatric disorders.

Authors:  Gislaine T Rezin; Graziela Amboni; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2008-11-01       Impact factor: 3.996

Review 10.  Psychosis related to neurological conditions: pro and cons of the dis- / mis-connectivity models of schizophrenia.

Authors:  Jack R Foucher; David Luck
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.